Total amount raised
$894.3 Millions
Latest funding date
Location
Treeline Biosciences has recently expanded its investor syndicate, securing significant capital commitments from KKR's Health Care Strategic Growth Fund II and other prominent investors. This Series A round of funding ensures the company has the resources to advance its pipeline for treating cancer and other serious diseases.
Keep reading to explore the intricacies of Treeline Biosciences' fundraising journey and the investors backing this innovative platform.
What Is Treeline Biosciences?
Treeline Biosciences is a biotechnology company dedicated to developing treatments for cancer and other serious diseases. The company operates from three locations: San Diego, Stamford, and Watertown, and has built a team of over 130 people.
Founded by Josh and Jeff, Treeline Biosciences emphasizes a data-driven approach to scientific research. The company has received significant financial backing, enabling it to pursue both long-term and short-term projects in the biotech industry.
How Much Funding Has Treeline Biosciences Raised?
- Funding Round: Series A
- Amount Raised: $212M
- Date: April 2021
- Lead Investors: ARCH Venture Partners, Google Ventures, OrbiMed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To build the company's pipeline and advance oncology research.
- Funding Round: Series A
- Amount Raised: $261.3M
- Date: October 2022
- Lead Investors: Kohlberg Kravis Roberts
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the development of Treeline Biosciences' oncology pipeline and hire additional staff.
- Funding Round: Funding Round
- Amount Raised: $421M
- Date: October 2024
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further advance the company's research and development efforts in oncology.
Total Amount Raised: $894.3M. Current Valuation: Not publicly disclosed.
Key Investors
- Rock Springs Capital
- Details: Rock Springs Capital is a healthcare-focused investment firm. They specialize in investing in companies within the healthcare sector.
- Investment Focus Areas: Healthcare
- Notable Investments: Not publicly disclosed
- OrbiMed
- Details: OrbiMed is a leading investment firm dedicated to the healthcare sector. They have a diverse portfolio that includes public and private companies.
- Investment Focus Areas: Biotechnology, Pharmaceuticals, Medical Devices
- Notable Investments: Not publicly disclosed
- Access Industries
- Details: Access Industries is a privately held industrial group with investments in various sectors. They are known for their diverse investment portfolio.
- Investment Focus Areas: Natural Resources, Chemicals, Media, Telecommunications
- Notable Investments: Not publicly disclosed
- ARCH Venture Partners
- Details: ARCH Venture Partners is a venture capital firm that invests in the development of seed and early-stage advanced technology companies. They focus on innovative and high-potential startups.
- Investment Focus Areas: Advanced Technology, Early-Stage Companies
- Notable Investments: Not publicly disclosed
- Kohlberg Kravis Roberts
- Details: Kohlberg Kravis Roberts (KKR) is a global investment firm that manages multiple alternative asset classes. They have a strong presence in private equity and other investment areas.
- Investment Focus Areas: Private Equity, Infrastructure, Real Estate
- Notable Investments: Not publicly disclosed
What's Next for Treeline Biosciences?
Treeline Biosciences stands at the cusp of significant opportunities, bolstered by substantial funding and a strong leadership team. With $473 million raised to date, the company is well-positioned to advance its oncology research and potentially develop groundbreaking cancer treatments. The robust funding landscape in the oncology sector, which has seen over $6 billion this year, further underscores the vast market potential.
Future fundraising prospects look promising as Treeline continues to attract investor interest. Demonstrating tangible progress in drug development will be crucial for securing additional capital. However, the company faces challenges, including high expectations from investors and the competitive nature of the biotech industry. Navigating regulatory hurdles and the lengthy drug approval process will also be critical as Treeline Biosciences strives to make a lasting impact in oncology.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Treeline Biosciences and gather other critical business insights.
Sign up for free to start exploring the wealth of information available at your fingertips.
